MW Creators

World News

Critical Limb Ischemia Market to Witness Upsurge in Growth During the Forecast Period 2030, Examine DelveInsight | Key Companies -Libella Gene Therapeutics, Hemostemix, Pluristem, Cynata Therapeutics, Reven Pharma, and Others

DelveInsight’s “Critical Limb Ischemia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Critical Limb Ischemia market trends in the seven major markets (7MM) (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The market report covers emerging drugs, current treatment practices, market share of the individual therapies, market drivers, barriers, unmet medical needs, current and forecasted market size from 2017 to 2030 segmented by seven major markets. 

Critical Limb Ischemia Disease Overview

Chronic limb-threatening Ischemia (CLTI), also known as Critical Limb Ischemia (CLI), is an advanced stage of peripheral artery disease (PAD). It is defined as ischemic rest pain, arterial insufficiency ulcers, and gangrene. The latter two conditions are jointly referred to as tissue loss, reflecting the development of surface damage to the limb tissue due to the most severe stage of ischemia.

Critical Limb Ischemia Market Key Facts

  • Eight to ten million Americans suffer from the arterial occlusive disease, leading to approximately 500–1,000 new cases of chronic limb ischemia per million people per year. The prevalence of critical limb ischemia is 12% in the adult population, with men affected slightly more than women. This prevalence is age-dependent as well, with nearly 20% of adults age 70 and older carrying a diagnosis of critical limb ischemia (Davies et. al., 2012).
  • As per the study conducted by Steve Duff et. al. titled “The burden of critical limb ischemia: a review of recent literature” CLI prevalence in the US adult population aged 40 or older is estimated to be 1.28%. With approximately 156 million US citizens in this age category, this prevalence estimate translates to approximately 2 million total CLI patients in the United States (2019).
  • According to DelveInsight’s findings, males are affected more as compared to females, in the case of Critical Limb Ischemia.


Key Benefits of Critical Limb Ischemia Market Report

  • The market report provides an in-depth analysis of Critical Limb Ischemia Market size, share, and epidemiology in 7MM.
  • The report will help in developing business strategies by understanding the trends & developments, key players operating in the market, and future competition that will drive and shape the market outlook in the upcoming years.
  • The report covers the factors stimulating the Critical Limb Ischemia market growth, current treatment practices, emerging drugs, market share of the individual therapies.
  • The report provides a detailed assessment of the patient population, unmet needs, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


Critical Limb Ischemia Market

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Critical Limb Ischemia market size and share by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology. 

The report gives a thorough detail of market trends, growth opportunities of each marketed and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Critical Limb Ischemia market size is expected to increase during the forecast period owing to the increased research and development activities and increased patient pool in 7MM.

Visit to get more detailed insights @

Critical Limb Ischemia Epidemiology

The epidemiology section covers insights about historical and current Critical Limb Ischemia patient pool and forecasted trends for every seven major markets from 2017 to 2030. It helps to recognize the causes of current and forecasted Critical Limb Ischemia epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Discover more about the epidemiological segmentation @

Critical Limb Ischemia Drugs Uptake and Key Market Players

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Critical Limb Ischemia market or expected to get launched in the market during the study period. The analysis covers the drug uptake; patient uptake by therapies; and sales of each drug.   

 Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Critical Limb Ischemia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent development such as collaborations, acquisitions, and mergers, licensing patent details, and other information.

Critical Limb Ischemia Therapeutics Analysis

The dynamics of the Critical Limb Ischemia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies and incremental healthcare spending across the world.

The key companies in the Critical Limb Ischemia market include:

  • Libella Gene Therapeutics
  • Hemostemix
  • Pluristem
  • Cynata Therapeutics
  • Reven Pharma

And others

Critical Limb Ischemia therapies covered in the report include:

  • ACP-01
  • CLBS12
  • CYP-002
  • Rejuveinix

And many more

For further information about the emerging therapies and key companies @


Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Critical Limb Ischemia Competitive Intelligence Analysis
  4. Critical Limb Ischemia Market Overview at a Glance
  5. Critical Limb Ischemia Disease Background and Overview
  6. Critical Limb Ischemia Patient Journey
  7. Critical Limb Ischemia Epidemiology and Patient Population
  8. Critical Limb Ischemia Treatment Algorithm, Current Treatment, and Medical Practices
  9. Critical Limb Ischemia Unmet Needs
  10. Key Endpoints of Critical Limb Ischemia Treatment
  11. Critical Limb Ischemia Marketed Products
  12. Critical Limb Ischemia Emerging Therapies
  13. Critical Limb Ischemia Seven Major Market Analysis
  14. Attribute Analysis
  15. Critical Limb Ischemia Market Outlook (7 major markets)
  16. Critical Limb Ischemia Access and Reimbursement Overview
  17. KOL Views on the Critical Limb Ischemia Market.
  18. Critical Limb Ischemia Market Drivers
  19. Critical Limb Ischemia Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get a Free Sample Copy of the Report @

Latest Reports By DelveInsight:

Critical Limb Ischemia Epidemiology Forecast

DelveInsight’s Critical Limb Ischemia – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Critical Limb Ischemia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Critical Limb Ischemia Pipeline Insights

Critical Limb Ischemia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Critical Limb Ischemia market.

Brain Hemorrhage Market

DelveInsight’s “Brain Hemorrhage Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Brain Hemorrhage market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Latest Healthcare Blogs By DelveInsight:


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Info:
Shruti Thakur
DelveInsight Business Research LLP
Phone No: +91-9650213330
Email: [email protected]
Connect With Us: LinkedIn | Facebook | Twitter
For Latest Update: Healthcare Blog
Request for Sample Copy of the Report at:

Leave a Reply

Your email address will not be published. Required fields are marked *